Relmada Therapeutics, Inc. RLMD Effective Income Tax Rate Reconciliation Adjustments To NOL Due To382Percentage

Effective Income Tax Rate Reconciliation Adjustments To NOL Due To382Percentage at other companies

Lightwave Logic, Inc.LWLG

-2.1%—

Capital City Bank GroupCCBG

-0.3%-0.5pp

Baxter InternationalBAX

-17.8%—

Cadence Design SystemsCDNS

-$382K-115%

Imperial OilIMO

-$5.25M+60.4%

The J.M. Smucker CompanySJM

-104.7%-196pp

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept rlmd:EffectiveIncomeTaxRateReconciliationAdjustmentsToNOLDueTo382Percentage.

The official record: Relmada Therapeutics, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s effective income tax rate reconciliation adjustments to NOL due to382percentage?: Relmada Therapeutics, Inc. (RLMD) reported effective income tax rate reconciliation adjustments to NOL due to382percentage of 6% in Q4 2025.
What does effective income tax rate reconciliation adjustments to NOL due to382percentage mean?: This represents the percentage adjustment to the effective tax rate caused by limitations on Net Operating Loss (NOL) carryforwards, often triggered by significant changes in ownership. It highlights tax constraints related to capital structure changes.